S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
New CBOE “special perk” helps traders target income every weekend (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
New CBOE “special perk” helps traders target income every weekend (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
New CBOE “special perk” helps traders target income every weekend (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
New CBOE “special perk” helps traders target income every weekend (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
New CBOE “special perk” helps traders target income every weekend (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
New CBOE “special perk” helps traders target income every weekend (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
New CBOE “special perk” helps traders target income every weekend (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
New CBOE “special perk” helps traders target income every weekend (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
New CBOE “special perk” helps traders target income every weekend (Ad)

Eledon Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ELDN)

$1.14
-0.01 (-0.87%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.12
$1.16
50-Day Range
$1.12
$1.69
52-Week Range
$1.07
$3.70
Volume
38,488 shs
Average Volume
58,054 shs
Market Capitalization
$27.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Eledon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
835.7% Upside
$10.67 Price Target
Short Interest
Healthy
0.27% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Eledon Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.89) to ($1.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

377th out of 957 stocks

Pharmaceutical Preparations Industry

165th out of 444 stocks


ELDN stock logo

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ELDN Stock Price History

ELDN Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Eledon Pharmaceuticals Appoints Eliezer Katz As Chief Medical Officer
See More Headlines
Receive ELDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELDN
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.67
High Stock Price Target
$13.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+835.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-87,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.70 per share
Book Value
$3.77 per share

Miscellaneous

Free Float
19,504,000
Market Cap
$27.59 million
Optionable
Not Optionable
Beta
1.64
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. David-Alexandre C. Gros M.D.Dr. David-Alexandre C. Gros M.D. (Age 51)
    Ph.D., CEO & Non Independent Director
    Comp: $807.96k
  • Dr. Steven N. Perrin Ph.D. (Age 57)
    President, Chief Scientific Officer & Non Independent Director
    Comp: $603.9k
  • Mr. Paul Sean Little (Age 58)
    CFO & Principal Accounting Officer
    Comp: $611.71k
  • Mr. John Herberger
    Vice President of Technical Operations
  • Mr. Bryan E. Smith J.D. (Age 43)
    General Counsel, Corporate Secretary & Chief Compliance Officer
    Comp: $377.14k
  • Dr. David Hovland Ph.D.
    Chief Regulatory Officer
  • Dr. Eliezer Katz F.A.C.S.
    FACS, M.D., Chief Medical Officer














ELDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eledon Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELDN shares.
View ELDN analyst ratings
or view top-rated stocks.

What is Eledon Pharmaceuticals' stock price target for 2024?

3 brokerages have issued 12-month price targets for Eledon Pharmaceuticals' shares. Their ELDN share price targets range from $9.00 to $13.00. On average, they anticipate the company's share price to reach $10.67 in the next year. This suggests a possible upside of 835.7% from the stock's current price.
View analysts price targets for ELDN
or view top-rated stocks among Wall Street analysts.

How have ELDN shares performed in 2023?

Eledon Pharmaceuticals' stock was trading at $2.28 at the start of the year. Since then, ELDN stock has decreased by 50.0% and is now trading at $1.14.
View the best growth stocks for 2023 here
.

Are investors shorting Eledon Pharmaceuticals?

Eledon Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 65,900 shares, an increase of 25.8% from the October 31st total of 52,400 shares. Based on an average trading volume of 88,800 shares, the days-to-cover ratio is currently 0.7 days.
View Eledon Pharmaceuticals' Short Interest
.

When is Eledon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ELDN earnings forecast
.

How were Eledon Pharmaceuticals' earnings last quarter?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) released its earnings results on Thursday, November, 9th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.06.

Who are Eledon Pharmaceuticals' major shareholders?

Eledon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (7.54%), Jmac Enterprises LLC (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David-Alexandre C Gros, David-Alexandre C Gros and Paul Sean Little.
View institutional ownership trends
.

How do I buy shares of Eledon Pharmaceuticals?

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ELDN) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -